Press Release.
MHRA grants marketing authorisation for e-Voke, the first electronic cigarette to be approved as a medicinal product.
Advent Life Sciences is pleased to announce that the e-Voke electronic inhaler (e-Voke) is the first ‘electronic cigarette-type’ device to be granted a license as a nicotine replacement therapy by the UK Medicines & Healthcare products Regulatory Agency (MHRA). e-Voke was originally developed by CN Creative Ltd, a former Advent Life Sciences portfolio company acquired by British American Tobacco in 2012.
e-Voke is similar in physical form to available, non approved, electronic cigarettes, but has been designed, developed and tested to meet the strict regulatory requirements of safety and consistency of a medicinal product. For the first time, smokers looking to reduce the harm caused by smoking cigarettes will have a safe and effective nicotine replacement product in the form of an electronic cigarette.
“The harm caused to smokers of conventional cigarettes is primarily from tar, carbon monoxide and carcinogens, yet the addiction is from nicotine – a much less harmful substance”
said Kaasim Mahmood, General Partner at Advent Life Sciences.
“e-Voke will allow smokers to manage their nicotine dependency while largely eliminating the toxic and carcinogenic substances in cigarettes, with the potential for very considerable health benefits. It is for this reason that we supported CN Creative and its founding entrepreneurs in their aim to develop a medically regulated e-cigarette”
he added.
“For the first time adults will have a true safer alternative to smoking, that has been through the rigor of medicinal regulation, a world’s first and a leap forward for the category and the consumer”
said David Newns, former Joint CEO of CN Creative.
About e-Voke:
e-Voke is used to relieve and prevent withdrawal symptoms and reduce the cravings smokers get when they try to stop smoking or when they cut down the number of cigarettes they smoke. e-Voke contains nicotine and belongs to a group of medicines known as nicotine replacement therapy (NRT). When smokers stop smoking or cut down the number of cigarettes they smoke, their body misses the nicotine that they have been getting from cigarettes. They may experience unpleasant feelings and a strong desire or craving to smoke. The nicotine they get from using e-Voke replaces the nicotine and relives the unpleasant withdrawal symptoms. It will also help to stop their craving to smoke.
About Advent Life Sciences:
Advent Life Sciences founds and invests in early- and mid-stage life sciences companies that have a first- or best-in-class approach to unmet medical needs. The investing team consists of 16 professionals, each with extensive scientific, medical and operational experience, a long-standing record of entrepreneurial and investment success in the US and Europe, and is particularly focused on supporting entrepreneurs and founders to take innovative new medical entities from concept to approval. The Firm invests in a range of sectors within life sciences, principally drug discovery, enabling technologies and med tech, always with an emphasis on innovative, paradigm-changing approaches. Advent Life Sciences has a presence in the UK, US and France.
